

This book offers the readers an insight and update on all aspects of diagnosis and treatment of bladder cancer. The contents are neatly divided into sections which deal with basic science and molecular markers, nuances and advances in surgical technology, debates and outcomes of non-muscle invasive and invasive bladder cancers, role of chemotherapy, pathogenesis and prognosis and finally quality of life assessments in these patients.

The first section “Precision medicine for individualized therapy” looks at the gene expression score in non-muscle invasive bladder cancer (NMIBC) and how this can help predict prognosis and improve outcomes in these patients. It also incorporates a personalised medicine approach in NMIBC with the use of novel next-generation sequencing. The expanding role of urinary biomarkers to diagnose new and recurrent tumours, oncological outcomes and progression of NMIBC is also covered. Disease progression in bladder cancer always remains a concern. This section also looks at several prognostic and predictive markers such as the identification of hypoxic gene-signature in high-risk bladder cancer, circulating tumor DNA for advanced bladder cancer, predictive model to muscle invasive bladder cancer (MIBC) and the role of immunotherapy for advanced cancers.

The second section “Novel advances in surgical technology” deals with the newer approaches of performing minimally invasive pelvic oncological procedures with laparoscopic single site surgery, robotic prostatectomy and robotic cystectomy.

The third section “Debates and experience in traditional surgical treatment” covers interesting and certain controversial areas involved in the management of radical cystectomy. This includes the influence of stent versus nephrostomy in the management of pre-cystectomy hydronephrosis, role of stenting for upper tract tumour recurrence and the role of enhanced recovery for early discharge following cystectomy. It also covers current concepts with prevention of venous thromboembolism, antiplatelet therapy and the effects of nutritional intervention prior to cystectomy.

Section four covers the “Progress in chemotherapy and medical treatment” in relation to bladder cancer. This includes topical mitomycin C (MMC), role and timing of neoadjuvant chemotherapy in locally advanced and metastatic bladder cancer, antibiotic prophylaxis and immunonutrition for these patients.

The fifth section talks about “Fresh vision of pathogenesis, development and prognosis” with impact of nutritional habits, lifestyle and frailty in bladder cancer patients. The relationship and influence of upper tract tumours along with the trends of bladder cancer and the role of national databases is also covered.

Finally, in the last section, the assessment and influence of health related quality of life (HRQoL) in bladder cancer is also covered along with the benefits of the new patient reported QoL measure “The bladder utility symptom scale”.

This book is an essential tool for oncologists, surgeons and researchers alike offering all aspects of bladder cancer management and is a must read for understanding current concepts and future perspectives of bladder cancer.



Bhaskar K. Somani

**Bhaskar K. Somani, MRCS, FEBU, FRCS (Urol)**  
Department of Urology,  
University Hospital Southampton NHS Trust,  
Southampton, UK